PDE5A and benign prostatic hyperplasia: Although some medical treatments have been developed to target bothersome voiding or/and storage symptoms associated with mLUTS, one of the PDE5 inhibitors (PDE5-Is), tadalafil, is a brand-new drug for treatment of mLUTS/BPH and is recommended as a level A in worldwide clinical treatment guidelines owing to various excellent evidence [4,5].